Characterizing this relationship would provide the ability to predict the time to steady-state ASP8232 concentration and the VAP-1 inhibition response to different ASP8232 concentrations, to identify individual covariate effects which influence this relationship, and to simulate the expected dose – PD response curve for DKD patients. This evidence concerns the gene AOC3 and diabetic kidney disease.